机构：[1]Shanghai Center for Systems Biomedicine, Ministry ofEducation Key Laboratory of Systems Biomedicine, and ShanghaiKey Laboratory of Gastric Neoplasms, Ruijin Hospital, Shanghai JiaoTong University, Shanghai, 200240, China [2]State Key Laboratory ofOncogenes and Related Genes, Shanghai Jiao Tong University,Shanghai, 200240, China [3]Department of Integrative Oncology,Shanghai Cancer Center, Fudan University, Shanghai, 200032, China [4]Department of Gastroenterology, the First Affiliated Hospital, FujianMedical University, Fuzhou, 350005, China [5]Shanghai East HospitalAffiliated to Tongji University, Shanghai, 200120, China [6]TongrenHospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200050, China [7]Shanghai Putuo Center Hospital,Shanghai, China [8]Shanghai Pudong Gongli Hospital, Shanghai, China200135 [9]Shanghai Fifth People’s Hospital affiliated to Fudan University, Shanghai, 200240 China [10]Department of Pharmacology andMolecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 [11]School of Biomedical Engineering,Shanghai Jiao Tong University, Shanghai, 200240, China
We aimed to globally discover serum biomarkers for diagnosis of gastric cancer (GC). GC serum autoantibodies were discovered and validated using serum samples from independent patient cohorts encompassing 1,401 participants divided into three groups, i. e. healthy, GC patients, and GC-related disease group. To discover biomarkers for GC, the human proteome microarray was first applied to screen specific autoantibodies in a total of 87 serum samples from GC patients and healthy controls. Potential biomarkers were identified via a statistical analysis protocol. Targeted protein microarrays with only the potential biomarkers were constructed and used to validate the candidate biomarkers using 914 samples. To provide further validation, the abundance of autoantibodies specific to the biomarker candidates was analyzed using enzymelinked immunosorbent assays. Receiver operating characteristic curves were generated to evaluate the diagnostic accuracy of the serum biomarkers. Finally, the efficacy of prognosis efficacy of the final four biomarkers was evaluated by analyzing the clinical records. The final panel of biomarkers consisting of COPS2, CTSF, NT5E, and TERF1 provides high diagnostic power, with 95% sensitivity and 92% specificity to differentiate GC patients from healthy individuals. Prognosis analysis showed that the panel could also serve as independent predictors of the overall GC patient survival. The panel of four serum biomarkers (COPS2, CTSF, NT5E, and TERF1) could serve as a noninvasive diagnostic index for GC, and the combination of them could potentially be used as a predictor of the overall GC survival rate.
基金：
National High Technology Research and Development Program of ChinaNational High Technology Research and Development Program of China [2012AA020103, 2012AA020203]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31370813, 91229106]; Science and Technology Commission of Shanghai Municipality Grants [12XD1403700, 13ZR1425600]; Key Projects in the National Science and Technology Pillar Program of China [2014BAI09B03]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA020103, R01AA020203] Funding Source: NIH RePORTER
第一作者机构：[1]Shanghai Center for Systems Biomedicine, Ministry ofEducation Key Laboratory of Systems Biomedicine, and ShanghaiKey Laboratory of Gastric Neoplasms, Ruijin Hospital, Shanghai JiaoTong University, Shanghai, 200240, China [2]State Key Laboratory ofOncogenes and Related Genes, Shanghai Jiao Tong University,Shanghai, 200240, China [3]Department of Integrative Oncology,Shanghai Cancer Center, Fudan University, Shanghai, 200032, China
共同第一作者：
通讯作者：
通讯机构：[1]Shanghai Center for Systems Biomedicine, Ministry ofEducation Key Laboratory of Systems Biomedicine, and ShanghaiKey Laboratory of Gastric Neoplasms, Ruijin Hospital, Shanghai JiaoTong University, Shanghai, 200240, China [2]State Key Laboratory ofOncogenes and Related Genes, Shanghai Jiao Tong University,Shanghai, 200240, China
推荐引用方式(GB/T 7714)：
Yang Lina,Wang Jingfang,Li Jianfang,et al.Identification of Serum Biomarkers for Gastric Cancer Diagnosis Using a Human Proteome Microarray[J].MOLECULAR & CELLULAR PROTEOMICS.2016,15(2):614-623.doi:10.1074/mcp.M115.051250.
APA：
Yang, Lina,Wang, Jingfang,Li, Jianfang,Zhang, Hainan,Guo, Shujuan...&Tao, Sheng-Ce.(2016).Identification of Serum Biomarkers for Gastric Cancer Diagnosis Using a Human Proteome Microarray.MOLECULAR & CELLULAR PROTEOMICS,15,(2)
MLA：
Yang, Lina,et al."Identification of Serum Biomarkers for Gastric Cancer Diagnosis Using a Human Proteome Microarray".MOLECULAR & CELLULAR PROTEOMICS 15..2(2016):614-623
生物学